iBio, Inc.

iBio, Inc. is a clinical-stage biotechnology company that uses Artificial Intelligence (AI) to develop precision antibodies for obesity, cardiometabolic, and cardiopulmonary diseases. The company's core mission is to use AI and machine learning (ML) to discover new biologic drugs that other scientists have not been able to develop. Through its AI Drug Discovery Platform, iBio has identified distinct molecules designed to address needs not met by current approved therapies. iBio believes that future obesity treatments should focus on the quality, durability, and tolerability of weight loss, not just overall weight loss. While current treatments like glucagon-like peptide-1 (GLP-1) receptor agonists have been a breakthrough, challenges remain, including muscle loss, fat regain after stopping treatment, and long-term tolerability. iBio is developing next-generation therapies to address these unmet needs by using AI-guided antibody design, advanced screening technologies, and expertise in biologics development. The company's strategy involves several key principles: developing next-generation antibody therapeutics to overcome limitations of current treatments, with the potential to preserve muscle mass, selectively target fat, and provide durable weight loss with improved tolerability. iBio prioritizes targets with strong human genetic and clinical validation to reduce translational risk and increase the likelihood of clinical success. It also evaluates opportunities in related obesity indications, including cardiometabolic and cardiopulmonary conditions such as pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF). Finally, iBio applies its integrated AI Drug Discovery Platform and scientific expertise to rapidly generate and advance development-ready biologics. Given that obesity is linked to various cardiometabolic and cardiopulmonary complications, iBio is also evaluating selected adjacent indications where its AI Drug Discovery Platform and target biology may offer distinct therapeutic opportunities.